Overview
Lobbying Costs
50,000€ - 99,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Medtech & Pharma Platform Association (MPP)
EU Transparency Register
234427831877-10 First registered on 25 Jun 2018
Goals / Remit
The Medtech & Pharma Platform Association (MPP) is a European cross-sectoral not-for-profit industry Association focusing on combined products, i.e. products that combine drugs, devices, diagnostics and/or digital elements to fulfill a medical purpose. Members are medtech, pharma and tech companies as well as organizations dedicated to enhancing synergies between the sectors. Current and future innovative healthcare solutions increasingly rely on combined products, integrating various combinations of pharma, medtech and digital technologies. MPP offers expertise and seeks dialogue with relevant stakeholders to collaborate on a proportionate regulatory framework for combined products, with a view to facilitate patient access to innovation, foster European competitiveness and enhance the safety of health data.
Main EU files targeted
The Medtech & Pharma Platform Association was founded in 2017 and started its activities in 2018.
The Medtech & Pharma Platform monitors EU legislative, policy and regulatory developments relating to combined products.
Specifically, the Medtech & Pharma Platform follows:
• Medical Devices Regulation EU 2017/745 & In vitro Diagnostics Regulation EU 2017/746
and their implementing and delegated acts as well as any related guidance document
• Medicinal Products Directive EU 2001/83
• Advanced Therapy Medicinal Product Regulation EU 1394/2007
• Regulation on Health Technology Assessment EU 2021/2282
• General Data Protection Regulation EU 2016/679
• Clinical Trials Regulation EU 536/2014
• Proposals for Data Governance Act and Data Act
• Proposal for Regulation on Artificial Intelligence
• Policy initiatives, projects, events and publications from DG SANTE, DG GROW, DG CONNECT, DG RESEARCH & INNOVATION
• European Health and Digital Executive Agency (HaDEA)
• Health emergency preparedness and response authority (HERA)
• EU Pharmaceutical Strategy
• Revision of the EU basic pharmaceutical legislation
• New Industrial strategy for Europe
• European Digital Strategy and Artificial Intelligence
• Horizon Europe
• European Health Data Space
• EU Beating Cancer Plan
• European Health Union
• Intellectual property action plan
• Institutional agreement Switzerland-EUAddress
Head Office
Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
Basel 4051
SWITZERLANDEU Office
Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
Basel 4051
SWITZERLANDWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Within the cluster of 25% working time, two people work 12.5% making a joint total of 25%. In total, 3 people are involved.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
N/A
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
50,000€ - 99,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
50,000€ - 99,999€
Other financial info
MPP is funded by membership contributions.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Stakeholder engagement, projects:
The MPP engages with relevant stakeholders on a European level, offers expertise and seeks dialogue to collaborate on a proportionate regulatory framework for combined products.
MPP has two active working groups:
• Working Group on Combined Products, focusing on co-packaged and non co-packaged drug-device-combinations and single integral combination products
• Working Group on Connected Combined Products, focusing on connected combined products including drugs, medical devices, in-vitro diagnostics, digital applications.
Publications:
• T.C. Kühler and al., Development and Regulation of Connected Combined Products: Reflections From the Medtech & Pharma Platform Association, Clinical Therapeutics, Volume 44, ISSUE 5, P768-782, 1 May 2022
• MPP Best Practice Guide for clinical trials with integral Drug-Device Combination Products including change control and usability studies, December 2020
• Position paper on the legislative framework for Connected Combined Products, October 2020
• Reflection paper on regulatory uncertainties for co-packaged and cross-labelled drug-device combinations under the new Medical Device Regulation, December 2019
• White Paper on EU regulatory and policy framework for combined products, October 2018
Events:
• MPP annual conference:The annual MPP conference is the leading event in the sector of products and solutions that combine pharma, medtech and digital components. The event is dedicated to enhancing synergies between these sectors. The conference provides a forum to exchange knowledge, identify new challenges and opportunities, initiate collaborations and propose improvements to regulatory frameworks and policy, toward the goal of improving patient access to innovative combined products
• MPP trainings & webinars: The MPP Association offers specialized, accredited training courses as well as webinars providing comprehensive and up-to-date insights on the latest regulatory and legislative developments related to combined products, medicinal products, medical devices, and in-vitro diagnostics.Other activities
MPP is acknowledged as Industry stakeholder for interaction with the European Medicines Agency (EMA)
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 15 Jun 2018 Location Brussels, Berl Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - MedTech Europe
- Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose
- European Plastics Converters Association
- European Confederation of Pharmaceutical Entrepreneurs
- European Federation of Pharmaceutical Industries and Associations
- EuropaBio
- MEDICINES FOR EUROPE
- European Coordination Committee of the Radiological, Electromedical and healthcare IT Industry
- Association of the European Self-Care Industry
- Meetings